articleTop 1% cited

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics · 2016 · Vol. 98(2) · pp. 275–285

William Morris✉(University of British Columbia)Scott Tyldesley(BC Cancer Agency)S. Rodda(University of British Columbia)Ross Halperin(University of British Columbia)Howard Pai(University of British Columbia)Michael McKenzie(University of British Columbia)Graeme Duncan(University of British Columbia)Gerard Morton(Health Sciences Centre)Jeremy Hamm(BC Cancer Agency)Nevin Murray(University of British Columbia)

View via DOI Publisher page

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Advanced Radiotherapy TechniquesMedicineClinical endpointProstate cancerBrachytherapyHazard ratioRandomized controlled trialAndrogen deprivation therapyUrologyRadiation therapySurvival analysis

MeSH terms

Re-IrradiationAge FactorsAgedAged, 80 and overAndrogen AntagonistsBrachytherapyCombined Modality TherapyFollow-Up StudiesHumansIodine RadioisotopesGonadotropin-Releasing HormoneMaleMiddle AgedPelvisProstatic Neoplasms

Citations

718

FWCI

64.83

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent